DelveInsight Evaluates a Robust Pipeline for Myelodysplastic Syndromes as Influential Pharma Players Set Foot in the MDS Landscape

Myelodysplastic Syndrome (MDS) pipeline landscape is going to boost in coming years owing to promising late-stage pipeline candidates and the entry of novel agents as new therapies.

/EIN News/ -- Las Vegas, USA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Pipeline for Myelodysplastic Syndrome as Influential Pharma Players Set Foot in the MDS Landscape

Myelodysplastic Syndrome (MDS) pipeline landscape is going to boost in coming years owing to promising late-stage pipeline candidates and the entry of novel agents as new therapies.

DelveInsight’s ‘Myelodysplastic Syndrome Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Myelodysplastic Syndrome pipeline domain. 

 Some of the salient features of the Myelodysplastic Syndrome Pipeline report:

• DelveInsight’s Myelodysplastic Syndrome Pipeline analysis presents the MDS domain with 100+ active players in the domain investigating 100+ pipeline therapies. 
• Many key companies are developing potential drug candidates to improve the ongoing Myelodysplastic Syndrome treatment, such as Horizon Pharma USA, Gilead Sciences, Astex Pharmaceuticals, Syntrix Biosystems, Syros Pharmaceuticals, Aprea Therapeutics, Celgene Corporation, Salarius Pharmaceuticals, Novartis Pharmaceuticals, and others. 
• Emerging Myelodysplastic Syndrome pipeline therapies such as IFN-γ (interferon gamma-1b) injection, Magrolimab, ASTX030, SX-682, Tamibarotene, APR-246, Luspatercept, Seclidemstat, MBG453, and others are under investigation in different phases of clinical trials.
• In September 2021, Jasper Therapeutics announced the initiation of a Phase I/II clinical trial to evaluate JSP191 as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related Myelodysplastic Syndrome (MDS). Jasper Therapeutics and the National Cancer Institute (NCI), part of the National Institutes of Health, had entered into a clinical trial agreement in which NCI will serve as the Investigational New Drug (IND) sponsor for this study.
• In July 2021, Roche announced that Venclexta (venetoclax) in combination with azacitidine had been granted Breakthrough Therapy Designation (BTD) by the US FDA for the treatment of adult patients with previously untreated intermediate, high- and very high-risk Myelodysplastic Syndrome (MDS) based on the revised International Prognostic Scoring System (IPSS-R).
• In August 2020, Keros Therapeutics initiated a study to develop a candidate for treating low blood cell counts or cytopenias. It includes anaemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

Request for Sample to know which MDS pipeline therapy is anticipated to be at the front in the coming years @ Myelodysplastic Syndrome Pipeline Therapeutics Assessment

The Myelodysplastic Syndrome pipeline report offers detailed profiles of the pipeline assets and the inactive and dormant assets, comparative analysis of clinical and non-clinical stage Myelodysplastic Syndrome products, comprehensive assessment of driving and restraining factors along with the opportunities and risks in the MDS pipeline landscape.

Myelodysplastic Syndrome Overview

Myelodysplastic Syndrome is a group of cancers in which immature blood cells in the bone marrow do not mature, so they do not become healthy blood cells. Myelodysplastic Syndrome is divided into subtypes based on blood cells — red cells, white cells, and platelets.

Myelodysplastic Syndrome rarely causes signs or symptoms in the early stages. In time, MDS might cause fatigue, shortness of breath, unusual paleness due to a low red blood cell count (anaemia), unusual bruising or bleeding due to a low blood platelet count (thrombocytopenia).

Myelodysplastic Syndrome Pipeline Drugs

Drug	Company	Phase	MoA	RoA
Magrolimab	Gilead Sciences	Phase III	CD47 antigen inhibitors	Intravenous
ASTX030	Astex Pharmaceuticals	Phase II/III	Cytidine deaminase inhibitors	Oral
SX-682	Syntrix Biosystems	Phase I/II	Interleukin 8 receptor antagonists	Oral
Tamibarotene	Syros Pharmaceuticals	Phase III	Retinoic acid receptor alpha agonists	Oral
APR-246	Aprea Therapeutics	Phase III	Thioredoxin reductase inhibitors	Intravenous
Seclidemstat	Salarius Pharmaceuticals	Phase I/II	Lysine specific demethylase 1 inhibitors	Oral
MBG453	Novartis Pharmaceuticals	Phase III	HAVCR2 protein inhibitors	Intravenous

Explore more about Myelodysplastic Syndrome novel pipeline therapeutic landscape @ Myelodysplastic Syndrome Pipeline Novel and Emerging Drugs

Myelodysplastic Syndrome Therapeutics Assessment

The Myelodysplastic Syndrome Pipeline report proffers an integral view of the Myelodysplastic syndrome emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono
• Combination

By Stage

• Discovery 
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By Molecule Type 

• Peptides
• Monoclonal Antibodies
• Small molecules
• Polysaccharides
• Immunotherapies

By Mechanism of Action

• CD47 antigen inhibitors
• Cytidine deaminase inhibitors
• Interleukin 8 receptor antagonists
• Retinoic acid receptor alpha agonists
• Thioredoxin reductase inhibitors
• HAVCR2 protein inhibitors

By Targets

• CD47 antigen
• Interleukin 8 receptor
• Cytidine deaminase
• Thioredoxin reductase
• HAVCR2 protein

Scope of the Myelodysplastic Syndrome Pipeline Report 

• Coverage: Global 
• Major Players: Horizon Pharma USA, Gilead Sciences, Astex Pharmaceuticals, Syntrix Biosystems, Syros Pharmaceuticals, Aprea Therapeutics, Celgene Corporation, Salarius Pharmaceuticals, Novartis Pharmaceuticals, and others.
• Key Myelodysplastic Syndrome Pipeline Theraṣpies: IFN-γ (interferon gamma-1b) injection, Magrolimab, ASTX030, SX-682, Tamibarotene, APR-246, Luspatercept, Seclidemstat, MBG453, and others.

Get a customized MDS pipeline report @ Myelodysplastic Syndrome Pipeline and Future Prospects 

Table of Contents 

1	Introduction
2	Executive Summary
3	Myelodysplastic Syndrome: Overview
4	Myelodysplastic Syndrome: Analytical Perspective In-depth Commercial Assessment
5	Pipeline Therapeutics
6	Late Stage Products (Phase III)
7	Mid Stage Products (Phase II)
8	Early Stage Products (Phase I)
9	Early Phase I
10	Therapeutic Assessment
11	Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Myelodysplastic Syndrome Key Companies
14	Myelodysplastic Syndrome Key Products
15	Myelodysplastic Syndrome - Unmet Needs
16	Myelodysplastic Syndrome - Market Drivers and Barriers
17	Myelodysplastic Syndrome - Future Perspectives and Conclusion
18	Myelodysplastic Syndrome Analyst Views
19	Appendix

Explore more about the scope of the report @ Myelodysplastic Syndrome Treatment & Clinical Trials

Track and assess a candidate’s clinical development journey through Actionable Intelligence, Key Cross Analysis and Detailed Profiling

Related Reports

Myelodysplastic Syndrome Market

DelveInsight's "Myelodysplastic Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends, current treatment practices, emerging drugs, Myelodysplastic Syndrome market share of the individual therapies, current and forecasted Myelodysplastic Syndrome market Size from 2017 to 2030.

Relapsed or Refractory Myelodysplastic Syndrome Pipeline

DelveInsight’s, “Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape covering the pipeline drug profiles, including clinical and non-clinical stage products, key companies like Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and many others.

Relapsed or Refractory Myelodysplastic Syndrome Market

DelveInsight's "Relapsed or Refractory Myelodysplastic Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Relapsed or Refractory Myelodysplastic Syndrome, market trends current treatment practices, emerging drugs, Myelodysplastic Syndrome market share of the individual therapies.

Myelodysplastic Syndrome with Excess Blasts2 Market

DelveInsight's "Myelodysplastic Syndrome with Excess Blasts2 - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myelodysplastic Syndrome with Excess Blasts2, current treatment practices, emerging drugs, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Myelodysplastic Syndrome with Excess Blasts2 Pipeline

"Myelodysplastic Syndrome with Excess Blasts2 Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Myelodysplastic Syndrome with Excess Blasts2 market.

Myelodysplastic Syndrome Epidemiology

DelveInsight's 'Myelodysplastic Syndrome - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Myelodysplastic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Checkpoint Inhibitor Refractory Cancer Market

DelveInsight’s ‘Checkpoint Inhibitor Refractory Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology, market drivers, market barriers, unmet medical needs, and key companies including Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, and Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC, Exicure, Inc., Evelo Biosciences, Inc./Merck Sharp & Dohme Corp,  Eisai, Kartos Therapeutics, Exelixis, Immunity Bio, and many others.

CAR-T Pipeline Insights

DelveInsight’s, “CAR-T – Pipeline Insights, 2021,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.

Acute Myeloid Leukemia Pipeline

DelveInsight’s, “Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, JW Pharmaceutical, Hanmi Pharmaceutical, GEMoaB Monoclonals, and several others.

Browse Through Our Blog Posts

Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth
Over the past few decades, the incidence and prevalence of Cancer have grown significantly which has resulted in low quality of life and the survival rate. 

Cervical Cancer Market Has A Lot Going On Under The Hood
Cervical cancer is the fourth most common type of cancer and the fourth leading cause of death in women. The year 2018 reported approximately 570 000 cases of cervical cancer. And 311 000 women died from the tumour.

Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia
The dynamics of the cancer cachexia market are expected to gain momentum as several companies are testing the waters, advancing the cancer cachexia pipeline.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us
                    
                    Shruti Thakur 
                    info@delveinsight.com 
                    +1(919)321-6187 
                    www.delveinsight.com